AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01193946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: dietary control
Description: Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
Study NCT01111565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram capsule administered orally, once daily without regard to meals.
Study NCT01111565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole capsule administered orally, once daily without regard to meals.
Study NCT02539251 — intervention group
Intervention type: BEHAVIORAL
Intervention: Arabic ASQ -3
Description: Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
Study NCT05145985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Senior Fitness Test
Description: Senior Fitness Test is comprised of 6 individual test items and for a description of the trials. All fitness tests (1-6) were selected for analysis:~1. Arm Curl (AC) - measurement of upper body muscle endurance - numbers of arm curls as possible in 30 seconds (n)~2. 30-second Chair Stand (30SCS) - measurement of lower body strength; numbers of chair stand as possible in 30 seconds (n)~3. Back Scratch Test (BST) - measurement of upper-body flexibility; the best score to the nearest centimeter (cm)~4. Chair Sit and Reach Test (CSRT)- measurement of lower-body flexibility (specifically hamstring flexibility); the best score to the nearest centimeter (cm)~5. 8-Foot Up and Go (TUG) - measurement of agility (dynamic balance) and aerobic endurance; the best time of the two trails to the nearest 1/10th second (s)~6. 2-Minute Walk Test (2MWT) - measurement of (aerobic) endurance; the total number of times the right knee reaches the tape level in two minutes (n)
Study NCT02624999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloVax™
Description: AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
Study NCT02624999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
Study NCT04142359 — intervention group
Intervention type: BIOLOGICAL
Intervention: BCG in Combination with N-803
Description: BCG in Combination with N-803
Study NCT04142359 — intervention group
Intervention type: DRUG
Intervention: N-803 alone
Description: N-803 alone
Study NCT00776477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel and aspirin
Description: clopidogrel 75mg daily and aspirin 100mg daily
Study NCT00776477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg daily
Study NCT02060539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity XR
Study NCT04553289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercising into pain
Description: the intervention consists in 4 strength exercises: one will be performed into pain (ranging between 4 and 7 on NPRS scale) and the rest between 0 adn 2 on a NPRS scale
Study NCT04553289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercising with no/slight pain
Description: the intervention consists in 4 strength exercises and all of them will be performed in no pain/slight pain (between 0 and 2 on NPRS scale)
Study NCT00542776 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
Study NCT02133222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT03570567 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Piranha Treatment
Description: The piranha device is used with an endoscope to breakup/dislodge the food bolus.
Study NCT04288102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: 3 does of UC-MSCs(4.0\*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.
Study NCT04288102 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline containing 1% Human serum albumin（solution without UC-MSCs）
Description: 3 does of placebo（intravenously at Day 0, Day 3, Day 6）
Study NCT04137744 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AXILLARY REVERSE MAPPING
Description: subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amsacrine
Description: one block amsacrine together with etoposide and methylprednisolone for very high risk patients
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofarabine
Description: one block clofarabine with Asparaginase for MRD positive patients after induction
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: part of different chemotherapy blocks in consolidation and reinduction
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin hydrochloride
Description: part of induction and reinduction therapy
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: part of reinduction therapy
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride
Description: part of reinduction therapy
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide phosphate
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: part of different chemotherapy blocks
Study NCT01228331 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine sulfate
Description: part of intravenous chemotherapy
Study NCT01228331 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-brain radiation therapy
Description: patients with initial cns involvement receive cranial irradiation
Study NCT01582841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MSI screening test
Description: All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
Study NCT02783027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SleepTrackTXT2
Description: Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
Study NCT03390764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4:1 closure group
Description: In this arm the incisions are closed by the 4:1-technique
Study NCT03390764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RTL plus 4:1 closure group
Description: In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
Study NCT02703181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epelsiban (GSK557296)
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
Study NCT02858466 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: MRI scan
Study NCT02858466 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI scan
Study NCT00521365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine 600mg
Description: 300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day.
Study NCT01929889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Access to Care
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Depression Screening
Description: Analysis of health care claims data for depression screenings at baseline and 12 months.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Patient-Provider Relationship
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Patient-Clinic Interactions
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Stigma
Description: Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Provider Continuity
Description: Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Symptom Severity
Description: Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Diagnoses
Description: Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Social support
Description: Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Preventive Screening
Description: Analysis of health care claims data for preventive screenings at baseline and 12 months.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Inpatient Hospitalization Utilization
Description: Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Inpatient Readmissions
Description: Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
Study NCT03034369 — intervention group
Intervention type: OTHER
Intervention: Post-Admission follow-up
Description: Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
Study NCT06380062 — intervention group
Intervention type: OTHER
Intervention: Plasma concentration of choline
Description: The exposure in this observational study is plasma concentrations of choline
Study NCT02776293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Study NCT02776293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Study NCT01694693 — intervention group
Intervention type: DRUG
Intervention: Orencia
Description: No Intervention
Study NCT03922880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
Study NCT03922880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
Study NCT03922880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
Study NCT03627832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, \& Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
Study NCT03627832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene
Description: All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study NCT03627832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
Study NCT04391257 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: geko™
Description: Assess if cardiac pacemakers detect geko™ electrical output pulse.
Study NCT02217748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey questionnaire
Study NCT03759925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Support
Description: Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
Study NCT03673891 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Life Flow
Description: LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
Study NCT01166256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 >92% or PaO2 >65 mmHg.
Study NCT01166256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula system
Description: High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 >92% or PaO2 >65 mmHg.
Study NCT02683109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC of tiotropium + olodaterol
Description: Fixed Dose Combination of tiotropium + olodaterol
Study NCT02683109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02683109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Study NCT02683109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olodaterol
Study NCT02830568 — intervention group
Intervention type: PROCEDURE
Intervention: open donor nephrectomy
Description: open donor nephrectomy
Study NCT02830568 — intervention group
Intervention type: PROCEDURE
Intervention: standard and hand-assisted laparoscopic donor nephrectomy
Description: standard and hand-assisted laparoscopic donor nephrectomy
Study NCT02830568 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic robotic-assisted nephrectomy
Description: laparoscopic robotic-assisted nephrectomy
Study NCT02987699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Study NCT02987699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
Study NCT02987699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fu, oxaliplatin , leucovorin
Description: Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
Study NCT03019848 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Study NCT03019848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01607164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Mood Project Website
Description: Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
Study NCT01884883 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PROTEOR Internal unicompartmental knee brace
Study NCT03350386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration
Study NCT03350386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaprozin
Description: Repeated administration
Study NCT03458377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational telephone call
Description: Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
Study NCT03290430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Counseling
Description: 8 sessions over 4 weeks. Lasting 1-2 hours each
Study NCT03290430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Counseling
Description: 8 in person sessions over 4 weeks. Lasting 30-45 minutes each
Study NCT03290430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Counseling
Description: 8 phone sessions over 4 weeks. Lasting 30-45 minutes each
Study NCT02703181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GSK557296
Description: White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
Study NCT04238949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker added to diabetes team
Description: A Community Health Worker will be added to the diabetes team caring for a child with new onset type 1 diabetes for 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
Study NCT04490759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra System
Description: Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Study NCT02330705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG
Description: Women will be given HCG before IUI